Urine tests effectively screen for HPV, but more data is needed to determine whether they can correctly diagnose cervical disease.
The highest rates of cervical cancer occur in women aged 65 to 69, according to new estimates. This suggests that screening guidelines may need to be reconsidered.
New research, led by Connie Trimble, MD, shows that vaccine treatments for women with high-grade cervical dysplasia can trigger an immune response that may induce some lesions to resolve.
New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.
Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.
Diagnosis and treatment of high-grade cervical dysplasia substantially increases the risk of cervical or vaginal cancer at or after age 60 years, a study finds.
A simple blood test using plasma thermogram could serve as an effective new indicator for detecting cervical cancer, including assessment of the cancer’s stage.
Researchers discovered 13 gene mutations of significance in cervical cancer, including 8 mutations not previously linked to cervical cancer and 2 mutations novel to any type of cancer.
Female providers were twice as likely as their male counterparts to order HPV testing for low-risk women aged 30 to 65 who had normal Pap smear results.
Retinoids may have some effect on regression of certain grades of cervical intraepithelial neoplasia (CIN) but do not prevent disease progression.